secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2024-06-24T23:59:59+00:00
Accession:  0001140361-24-031087
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio shareholders approve all proposals, including 6.5M share increase to equity plan
--------------------------------------------------------------------------------

- All five director nominees elected: Eric Aguiar, Jennifer Cook, Andrea Ellis, Fred Hassan, Ali Satvat.
- Advisory say-on-pay vote passed with ~134.3M for, ~9.3M against.
- Deloitte & Touche ratified as independent auditor for fiscal 2024.
- 2021 Stock Plan amended to increase shares reserved by 6.5 million.
- Broker non-votes were 17.3M on director election and most other proposals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000114036124031087/0001140361-24-031087-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000114036124031087/ef20031581_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-031087

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer